Vident Advisory’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$393K Buy
6,688
+39
+0.6% +$1.64K ﹤0.01% 1485
2026
Q1
$214K Buy
6,649
+602
+10% +$22.3K ﹤0.01% 1670
2025
Q4
$255K Sell
6,047
-310
-5% -$12.5K ﹤0.01% 1448
2025
Q3
$218K Buy
+6,357
New +$182K ﹤0.01% 1534
2025
Q1
– Sell
-9,199
Closed -$364K – 1636
2024
Q4
$364K Buy
+9,199
New +$348K 0.01% 1089
2024
Q3
– Sell
-16,084
Closed -$349K – 1560
2024
Q2
$349K Sell
16,084
-768
-5% -$16.1K 0.01% 1065
2024
Q1
$373K Buy
16,852
+1,081
+7% +$26.4K 0.01% 937
2023
Q4
$434K Sell
15,771
-8,895
-36% -$215K 0.01% 839
2023
Q3
$551K Buy
+24,666
New +$634K 0.02% 672

Other funds holding VCYT

Vident Advisory's VCYT Position: Q2 2026 in Review

Vident Advisory increased its Veracyte (VCYT) stake by 0.59% in Q2 2026, buying an estimated $1.64K and bringing the position to 6,688 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

Vident Advisory first reported a position in VCYT in Q3 2023 and has held it in 9 quarters since. The position peaked at $551K in Q3 2023. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Vident Advisory held 6,688 shares of Veracyte worth $393K as of Q2 2026.
  • Vident Advisory bought 39 Veracyte shares in Q2 2026, an estimated $1.64K.
  • Veracyte made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1485 holding.
  • Vident Advisory first reported a position in Veracyte in Q3 2023 and has held it in 9 quarters since.
  • Vident Advisory's Veracyte position peaked at $551K in Q3 2023.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.